MaxCyte (NASDAQ:MXCT) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of MaxCyte (NASDAQ:MXCT) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $7.00.

MaxCyte Price Performance

Shares of MXCT stock opened at $0.81 on Friday. MaxCyte has a fifty-two week low of $0.75 and a fifty-two week high of $4.49. The firm’s 50 day moving average price is $1.36 and its two-hundred day moving average price is $1.52. The stock has a market cap of $86.19 million, a price-to-earnings ratio of -1.84 and a beta of 1.21.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The business had revenue of $6.41 million during the quarter, compared to analysts’ expectations of $8.37 million. On average, equities analysts forecast that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Trading of MaxCyte

Institutional investors have recently added to or reduced their stakes in the stock. Mirabella Financial Services LLP grew its holdings in MaxCyte by 78.4% during the 2nd quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company’s stock worth $14,388,000 after acquiring an additional 2,900,000 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of MaxCyte in the 3rd quarter valued at about $3,330,000. AXA S.A. lifted its position in shares of MaxCyte by 123.2% during the second quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after purchasing an additional 1,215,481 shares during the last quarter. Willis Investment Counsel increased its holdings in MaxCyte by 126.8% in the third quarter. Willis Investment Counsel now owns 862,758 shares of the company’s stock valued at $1,363,000 after buying an additional 482,287 shares during the last quarter. Finally, UBS Group AG increased its holdings in MaxCyte by 186.3% in the third quarter. UBS Group AG now owns 474,487 shares of the company’s stock valued at $750,000 after buying an additional 308,769 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.